Biotech stock Halozyme Therapeutics is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ:BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...

Scams involving celebrities or other famous people aren't really new - and are simply a modern take on the "Spanish Prisoner" or "Nigerian Prince" schemes ...

OpenAI’s Sam Altman isn’t keen on potential Musk takeover, BP promises big reset as earnings hit 4-year low, and more news to ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly exceeded analyst forecasts for both sales and earnings in Q4 2024. As has been true for a while, sales of GLP-1 drugs Mounjaro and Zepbound drove both sales and earnings growth.

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts ...

This is a great tragedy; many investors will be morally inclined to support Eli Lilly as well as financially. I expect that this moral stance will only help to sustain sentiment for the stock as ...

Over the past 3 years, the stock has been up almost 250% while generating $1.5 per share in dividends. I’ve been bullish on Eli Lilly for a while, and the recent pullback makes this reliable ...

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...